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Abstract
Functional inactivation of the von Hippel-Lindau (VHL) tumor suppressor protein is linked to the development of several
forms of cancer as well as oncogenic progression like sporadic renal clear-cell carcinomas (RCC). Despite the critical role
played by VHL in destruction of hypoxia-inducible factor a (HIFa) via ubiquitin-mediated proteolysis, very little is known
about the post-translational modification which regulates VHL activity. Our previous study showed that the SUMO E3 ligase
PIASy interacts with VHL and induces VHL SUMOylation on lysine residue 171 (Cai et al, PLoS ONE, 2010, 5(3):e9720). Here we
further report that VHL also undergoes ubiquitylation on both lysine residues 171 and 196, which is blocked by PIASy.
Moreover, using a VHL-SUMO1 or ubiquitin fusion protein, we found that ubiquitylated VHL is localized predominantly in
the cytoplasm, while SUMOylated VHL results in increased VHL protein stability and nuclear redistribution. Interestingly,
substitution of lysine 171 and 196 to arginine of VHL abrogates its inhibitory function on the transcriptional activity of HIFa,
and tube formation in vitro. This demonstrates that post-translational modifications like ubiquitylation and SUMOylation
contributes to VHL protein stability and nucleocytoplasmic shuttling, and that the overall function of VHL in tumor
suppression may require a precise and dynamically regulated process which involves protein modification.
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Introduction
The von Hippel-Lindau (VHL) gene was identified as a tumor
suppressor in 1993 [1]. Germ-line mutations in this gene causes
VHL hereditary cancer syndrome, which is characterized by the
development of tumors of the central nervous system (CNS),
kidney, eye, and pancreas [2,3]. Somatic mutations of the VHL
gene also has been widely demonstrated in the majority of
sporadic renal clear-cell carcinomas (RCCs, the most common
form of adult kidney cancer) [4–6], and cerebellar hemangioblas-
tomas [7]. Reintroduction of wild type VHL into VHL
2/2 renal
carcinoma cells (RCC) has been shown to sufficiently suppresses
tumor formation in vivo [8]. In the 3D protein structure, the VHL
protein contains two functional domains, a and b. The a domain
binds to elongin C and the b domain acts as the substrate-
recognition site for targeting proteins [9]. Many studies have
demonstrated that VHL is a multi-purpose adaptor protein that
engages in regulation of the extracellular matrix [10,11], cellular
differentiation [12], cell cycle [13], cell survival, apoptosis [14–16],
and senescence [17]. However, the main function of VHL is
viewed as an adapter for targeting hypoxia-inducible factor (HIF)
a subunit for proteolytic degradation [18,19].
In the presence of oxygen, HIFa is hydroxylated by prolyl
hydroxylase (PHD) and then binds to VHL for proteasome-
mediated degradation through the formationofEC2V (ElonginBC-
Cul2-VHL) E3 ubiquitin ligase complex [18–20]. Under hypoxic
environment, this hydroxylation-mediated degradation pathway is
blocked, and results in HIFa translocation and accumulation in the
nucleus, where it binds with the constitutively expressed HIFb to
form a heterodimer and transactivates hypoxia-responsive genes
(including Glut-1 and VEGF) that are implicated in cellular
metabolism, angiogenesis, invasion, and metastasis [21,22]. Thus,
loss function of VHL or hypoxic conditions will lead to HIFa
accumulation and will also impair several other VHL-modulated
biological pathways associated with tumor suppression.
Degradation of nuclear substrates by the ubiquitylation depen-
dent system often requires nuclear-cytoplasmic trafficking of both
the E3 ubiquitin ligase and the substrate proteins [23]. As a
ubiquitin E3 ligase, it has been viewed that VHL is dynamic in
controlling the degradation of HIFa, and several physiological cues
can modulate the function of VHL within this setting [24]. For
instance, VHL is predominantly nuclear at low cell density and
cytoplasmic at high cell density [25]. Additionally, upon transcrip-
tional arrest or low pH, VHL will accumulate in the nucleus
[26,27]. Although the biological significance of this is unclear, the
evidence supports the notion that nucleocytoplasmic shuttling of
VHL may be important for its antitumor effects. Notably, by using
various nuclear import or export sequences fused with VHL, a
previous study has indirectly showed that specific subcellular
localization affects the antitumor properties of VHL [28].
To date protein posttranslational modification by ubiquitin or
other ubiquitin-like molecules (i.e. SUMO, NEDD) has emerged as
an important strategy for dynamically regulating target proteins
involvedinregulationofdiverse cellularprocesses, including protein
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12636relocalization, stability and stress response [29–31]. We and other
groups have previously found that SUMOylation or Neddylation of
VHL is able to affect its function in tumor suppression [32–34]. To
determine whether the posttranslational modification of VHL
affects its protein stability and nucleocytoplasmic redistribution, we
furtherinvestigatedthe modificationof VHL by mutationofspecific
lysine residues. Our previous finding showed that PIASy (a SUMO
E3 ligase) induces VHL SUMOylation [32]. In the present study,
we further showed that VHL is also ubiquitylated on both lysines
171 and 196, and that coexpression of PIASy prevents VHL
ubiquitylation. Furthermore, we also demonstrated that VHL with
ubiquitin or SUMO modification at high cell density exhibited
distinct subcellular distribution and protein stability. The mutation
of VHL lysine 171/196 which abrogates its ubiquitin and SUMO
modification disabled its function related to inhibition of HIFa
transcriptional activity and tube formation. Therefore, the ubiqui-
tin/SUMO modification of VHL allows for precise regulation of
VHL nucleocytoplasmic trafficking, and disruption of this process
can impair its antitumor effects.
Results
Lysine residues 171 and 196 of VHL are targeted for
ubiquitylation
Previous studies have demonstrated that VHL is a major player
in the ubiquitylation system by acting as an ubiquitin E3 ligase.
However, recent studies has shown that VHL is targeted for
proteasomal degradation by cellular or viral proteins (like E2-EPF
UCP and KSHV LANA) [35,36]. To investigate whether VHL
itself can be ubiquitylated, we overexpressed FLAG-tagged VHL
in the presence or absence of HA-tagged ubiquitin in HEK293
cells followed by treatment with or without proteasome inhibitor
MG132, and then performed immunoprecipitation and immuno-
blotting with FLAG antibody. The results showed that VHL had
two slower-migrating bands (ubVHL) which appeared when
coexpressed with ubiquitin (Figure 1A, compare lane 3 with 2),
and the increase intensity of the modified ubVHL bands consistent
with higher levels of ubiquitin after proteasomal inhibitor MG132
treatment, further proving that ubVHL is the isoform of VHL with
ubiquitin modification (Figure 1A, compare lane 6 with 3). To
determine which lysine residues are required for the ubiquitylation
of VHL, we generated a series of VHL mutants (K171R, K196R,
K171,196R, K159R, and 3KR) based on all the lysine residues with
potential modification (like SUMOylation and Neddylation
indicated in Figure 1B), and then coexpressed with exogenous
HA-tagged ubiquitin in HEK293 cells. Figure 1C showed that
among three mutants (K159R, K171R, and K196R) with the
single residue mutation, only K171R and K196R showed a
significant reduction in the intensity of the modified isoform
ubVHL when compared to wild type VHL. Furthermore, the
double mutant K171,196R, similar to the triple mutant 3KR, almost
completely lost the modified bands (Figure 1C, compare lane 5
Figure 1. VHL can be ubiquitylated on lysines 171 and 196. (A) The level of ubiquitylated VHL is increased by proteasomal inhibitor
treatment. HEK293 cells were individually cotransfected with expression vector encoding the indicated proteins in the top panel. Forty-eight hour
posttransfection, the cells were treated with or without 20 mM MG132 for 2 hrs before harvest. Cell extracts were subjected to immunoprecipitated
(IP) and immunoblotting (IB) as indicated in the figure. The relative quantitation of VHL ubiquitylation (ubVHL) was presented at the bottom. (B)
Schematic representation of VHL a and b domains with three potentially modification lysines K159, K171 and K196. Su, SUMOylation; Ub,
ubiquitylation; Nedd, Neddylation; AD, acidic domain; OD, oligomerization domain. (C) Lysine 171 and 196 but not 159 of VHL occurs ubiquitylation
in vivo. HEK293 cells cotransfected with expression vector encoding the indicated proteins in the top panel, were treated with 20 mM MG132 for 2 hrs
before harvest and subjected to immunoprecipitated (IP) and immunoblotting (IB) as indicated in the figure. (D) PIASy suppresses VHL ubiquitylation.
As performed in panel C, HEK293 cells were transfected with indicated plasmids. WCL, whole cell lysate; HC, heavy chain; LC, light chain. The asterisk
denotes uncharacterized protein band.
doi:10.1371/journal.pone.0012636.g001
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residues are the major residues for ubiquitin modification but not
lysine 159. The re-immunoblotting results showing that the double
(K171,196R) and triple (3KR) mutants present less association with
ubiquitin than wild type of VHL (Figure 1C, middle panel),
suggest that lysines 171 and 196 modification contribute to the
ubiquitylation function of VHL.
VHL ubiquitylation is blocked by PIASy and its protein
stability and nuclear localization is increased
Previously we reported that SUMOylation occurs on lysine 171
of VHL [32]. To determine whether PIASy could prevent VHL
ubiquitylation in addition to stimulating SUMOylation, we studied
the effects of PIASy on both wild type VHL and the SUMOyla-
tion-deficient mutant K171R (that could still be ubiquitylated to
some extent on lysine 196). Figure 1D showed that coexpression of
PIASy completely suppressed the ubiquitylation of VHL on either
lysine 171 or 196. This suggests that PIASy plays a role in
stabilization of VHL by blocking ubiquitylation. To further assess
the role of PIASy on VHL protein stability, we used cycloheximide
to block protein synthesis and examined the stability of wild type
VHL when cotransfected with either the plasmid expressing full-
length (FL) PIASy or a PIASy mutant which lacks the ability to
bind VHL (DC) in HEK293 cells. As shown in Figure 2A, VHL
stability was significantly increased in the presence of wild type
PIASy but not its mutant which lacks VHL-binding ability. The
overall role of PIASy on VHL stability was further confirmed by
the observation that the half life of endogenous VHL is decreased
when endogenous PIASy expression is knocked-down (Figure 2B).
Similarly, to determine the effect of ubiquitylation on VHL
protein stability, we utilized the same strategy along with or
without treatment with the proteasomal inhibitor MG132 to test
the stability of wild type VHL and its ubiquitylated-site specific
mutants (K171R or K196R). The results showed that MG132
treatment significantly increases the half life of wild type VHL
when compared with no MG132 treatment. Consistently, the
mutation of ubiquitylated lysine residue 171 or 196 leads to
increased stability of wild type VHL (Figure 2A, lower panels).
Therefore, these results indicate that in addition to SUMOylation,
the lysine 171 of VHL is also targeted for ubiquitylation and
degradation, and further supports a role for lysine 196 as an
alternative target for VHL ubiquitylation, and that PIASy can
function to increase VHL stability by blocking its ubiquitylation.
A number of studies have shown that the process of ubiquitin
and ubiquitin-like modification not only increases target protein
stability but also contributes to nuclear localization of target
proteins [29–31]. To explore whether the subcellular localization
of VHL is influenced by interaction with PIASy and its deficiency
of ubiquitin/SUMO modification, we investigated the subcellular
localization of wild type VHL and its K171R mutant in the
Figure 2. The VHL protein stability is enhanced by lysine 196 mutation and PIASy coexpression. (A) Proteasomal inhibitor MG132,
Lys196 mutation or PIASy coexpression increases VHL protein stability. HEK293 cells were cotransfected with plasmids expressing wild type (WT) VHL,
VHL plus full length PIASy or its deletion mutant (DC) of VHL-binding domain, or VHL K196R alone. 48 h post-transfection, cell lysates treated with
cycloheximide (CHX, 100 mg/ml) for 0, 1, 2 and 4 hours in the presence or absence of MG132 was subjected to immunoblot as indicated. b-Actin
immunoblotting was used as the loading control. The relative quantitation of VHL is shown in bottom panel. (B) PIASy knockdown reduces VHL
protein stability. HEK293 cells were individually infected by lentivrus expressing small hair RNA against PIASy (shPIASy) or luciferase (shLuc). The
infected cells after puromycin (1 mg/ml) selection were treated with cycloheximide, lysated and then subjected to immunoblot as described in
panel A.
doi:10.1371/journal.pone.0012636.g002
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cence assays. In contrast to wild type VHL, the localization pattern
of K171R mutant showed a slight increase in nuclear localization
(Figure 3A and B, left panels). Moreover, when PIASy was
coexpressed, the K171R mutant dramatically localized to the
nucleus but lost the punctate foci which overlapped with PIASy in
786-O cells (Figure 3A and B, left panels). Unexpectedly, we also
observed that the foci staining pattern of PIASy in the
coexpression of wild type VHL is larger and less than in the
K171R mutant (Figure 3B, right panels, the enlarged region).
Similar results were also seen in the HEK293 cells with less
translocation efficiency (Figure 3A). In addition, the evidence of
VHL-interacting domain deletion of PIASy lost its effect on the
induction of VHL nuclear localization (Figure 3B, right lower
panel), further indicating that the punctate foci which represent
VHL staining are the dominant modified isoform of VHL on
lysine 171 due to PIASy induction. However, SUMO modification
of VHL is not a critical prerequisite for PIASy-mediated VHL
nuclear localization but may be important for localization in
specific subnuclear compartments. To further confirm that PIASy
does induce VHL nuclear localization, we individually extracted
nucleus and cytoplasm fractions from 786-O cells cotransfected
with full length PIASy, its mutant (DC) of the VHL-interacting
domain deletion or the empty vector alone in the presence of wild
type VHL. Consistent with the results from the immunofluores-
cence assays, the nuclear distribution of wild type VHL was greatly
Figure 3. PIASy alters VHL subcellular localization. Immunofluorescence assay of HEK293 (A) or 786-O (B) cells transfected with wild type (WT)
HA-VHL, its mutant K171R in the presence and absence of PIASy-RFP (red) coexpression were cultured on coverslips, fixed with 3% paraformaldehyde,
and then subjected to immunofluorescence assay followed by mouse anti-HA antibody (green) and nuclear staining (blue) with DAPI as indicated. (C)
Immunoblotting analysis. 786-O cells expressing HA-VHL in the presence or absence of PIASy-FLAG coexpression were subjected to nucleus (Nucl)
and cytoplasm (Cyto) proteins extract followed by immunoblotting against HA and FLAG antibodies. Nuclear protein Sp1 and cytoplasm protein b-
actin were blotted as fraction positive control. FL, full length; DC, the carboxyl domain deletion; ns, non-specific band. (D) PIASy knockdown reduces
endogenous VHL nuclear distribution. HEK293 cells with constitutively knockdown against PIASy (shPIASy) or luciferase (shLuc) were performed
nucleus (Nucl) and cytoplasm (Cyto) fraction assays as described in panel C.
doi:10.1371/journal.pone.0012636.g003
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deletion of VHL-interacting domain of PIASy (Figure 3C).
Moreover, the lentivirus-mediated knockdown inhibition of
endogenous PIASy expression in 293 cells dramatically reduced
nuclear localization of endogenous VHL (Figure 3D). Taken
together, these results further strengthen our hypothesis that
PIASy facilitates VHL nuclear localization and that SUMO
modification of VHL contributes to its colocalization with PIASy
in the subcellular nuclear compartment.
Ubiquitin/SUMO modification distinctly impairs VHL
protein stability and subcellular distribution
Despite the fact that some physiological conditions are able to
induce the constitutive shuttling of VHL between the nucleus and
cytoplasm compartment [26,27], the underlying molecular
mechanism still remains unclear. To explore whether ubiquitin
modification of VHL leads to nuclear export and SUMO
modification results in nuclear import, as well as whether
ubiquitylation and SUMOylation of VHL exhibits distinct protein
stability, we engineered the ubiquitin and SUMO modified VHL
(VHL-Ub
DGG and VHL-SUMO1
DC4) with a mutation in lysine
171 by utilizing an artificially fused protein strategy [32]. The
glycines which are critical for generating the covalent link were
removed in both fused ubiquitin and SUMO proteins to exclude
the possibility of the fusion protein acting as a ubiquitin or SUMO
like protein. The results showed that ubiquitylated VHL (VHL-
Ub
DGG) was exclusively located in the cytoplasm, while SUMOy-
lated VHL (VHL-SUMO1
DC4) predominantly existed in the
nucleus (Figure 4A). This provides evidence that ubiquitin and
SUMO modification of VHL can regulate VHL specific
subcellular localization. Consistently, the protein stability of
VHL where monitored by ubiquitin or SUMO modification and
showed reduced stability of VHL-Ub
DGG compared to VHL-
SUMO1
DC4 and may explain why VHL was more stable once
lysine 171 was mutated (Figure 4B).
Moreover, to determine whether the SUMO/Ubiquitin mod-
ification on lysine 171 of VHL influences the further ubiquitylation
on lysine 196 and alters VHL subcellular distribution, we
performed the ubiquitylation assays by individually coexpressing
ubiquitylated (VHL-Ub
DGG) and SUMOylated (VHL-SU-
MO1
DC4) form of VHL with or without lysine 196 mutation in
the presence of HA-Ub. The results showed that ubiquitin but not
SUMO1 modification increases the lysine 196 ubiquitylation
which is significantly abolished by lysine 196 mutation (Figure 4C).
Coordinately, in the nuclear and cytoplasm fractions, the result
showed that mutation of lysine 196 not only increases the nuclear
localization of SUMO1-modified VHL (VHL-SUMO1
DC4) but
also ubiquitin-modified VHL (VHL-Ub
DGG) (Figure 4D). Inter-
estingly, we also observed that the enhancement of nuclear
localization of VHL with either SUMO1 or ubiquitin modification
caused by the mutation at lysine 196 occurs with increase
oligomerization and are mostly distributed in the cytoplasm
compartment (Figure 4D, and the oligomerization definition
referred to [32]). This further corroborates the hypothesis that
localization in the nuclear compartment is a prerequisite for
inducing oligomerization despite the fact that oligomerized VHL
eventually goes to cytoplasm.
Mutation of lysine residues 171/196 abolishes the
inhibitory function of VHL on the transcriptional activity
of HIFa as well as tube formation
VHL functions as a tumor suppressor by targeting specific
proteins, including HIFa for degradation [24]. To ascertain if
mutation of ubiquitylated (K171 and 196) or SUMOylated (K171)
site is sufficient to inactivate the antitumor properties of VHL in
cancer cells, we tested whether mutation of lysine 171/196
resulted in disruption of VHL on inhibition of the transcriptional
activity of HIFa. The VHL-deficient 786-O cells were transiently
transfected with vector, vector expressing wild-type VHL or its
mutants along with HIFa responsive element driven luciferase
reporter. The results of the reporter assay showed that except for
the K159R mutant, both the K171R and K196R mutants
disrupted the inhibition of the transcriptional activity of HIFa
when compared to WT (Figure 5A). The double mutant of lysine
171/196 (K171,196R) and the triple mutant 159/171/196 (3KR)
showed the greatest efficiency of disruption of VHL inhibitory
activities (Figure 5A). Concordantly, in vitro endothelial tube
formation assay using conditioned medium from the supernatants
of the vector, VHL or K171,196R -expressing 786-O cells, showed
that the K171,196R mutation markedly reduced the inhibition of
tube formation compared to wild type VHL (Figure 5B). Thus,
these results demonstrate that modification on lysines 171/196 is
critical for VHL to function as a tumor suppressor.
Discussion
Functional inactivation of VHL is not only able to induce the
von-Hippel Lindau familial cancer syndrome but can also result in
sporadic renal carcinomas, and sporadic hemangioblastomas of
CNS [37]. VHL has been shown to associate with the inhibition of
several cellular processes including angiogenesis, cell cycle exit
[38,39] and fibronectin matrix assembly [10,11]. Importantly, the
ability of VHL to induce substrate proteolysis as a ubiquitin E3
ligase is critical to its function [18]. Previous studies have shown
that the function of a ubiquitin ligase can be regulated by
controlling the ligase or its substrate using a number of strategies
including posttranslational modifications, interactions with regu-
latory factors, or subcellular localization [24]. Recently, VHL was
shown to be Neddylated on lysine 159 and associated with the
fibronectin matrix assembly and suppression of tumor develop-
ment [33,34], however, these activities are not related to its E3
ligase activity. Therefore, the posttranslational modifications status
in regulation of VHL E3 ligase activity remains understudied. Our
previous studies have demonstrated that PIASy interacts with
VHL and induces VHL SUMOylation [32], and that the viral
protein LANA is able to promote VHL ubiquitylation and
degradation [36]. In this work, we further demonstrated that
VHL is ubiquitylated on lysine 171 and 196, and that enhanced
expression of the SUMO E3 ligase PIASy not only blocks VHL
ubiquitylation, but also increases VHL nuclear localization which
leads to protein stabilization. By using SUMO1 or ubiquitin fusion
VHL proteins, we have further showed that SUMO1 and
ubiquitin modified isoform of VHL exhibits reverse nucleocyto-
plasmic distribution. This suggests that reversible modification of
SUMO1 and ubiquitin is a strategy for dynamic regulation of
VHL nucleocytoplasmic shuttling. Interestingly, a single or double
mutation of lysine 171 and 196 or fusion with ubiquitin or
SUMO1 in VHL resulted in a decrease in HIFa inhibition when
compared to wild type VHL. The most significant of inactivation
was the SUMO1 modification followed by the double lysine 171/
196 mutation and the single mutation (Figure 5C). In addition, the
evidence of the increased nuclear localization of VHL-Ub
DGG
with lysine 196 mutation suggested that the regulation of lysine
196 is involved in controlling the process of VHL nucleus –
cytoplasm shuttling, and that this regulation may be associated
with PIASy interaction since we observed that VHL-Ub
DGG
interacts with PIASy in our previous studies [32]. These findings
Ub/SUMO Modified VHL
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steps in this dynamic regulatory process which involves posttrans-
lational modification will contribute to VHL nucleocytoplasmic
shuttling (Figure 5C).
To date, one of the difficulties in separating many of the
discrete cellular roles of VHL is that individual mutations in
the gene result in widespread changes to the protein’s function
[4–6]. Consistent with the previous reports [40], we found that
although mutation of ubiquitylated-sites increase VHL stability,
the mutants also significantly influenced the ubiquitin ligase
activity of VHL toward HIF1a. The explanation of this
phenomenon could be attributed to the ubiquitylation of VHL
related with proteasomal degradation. The ability of VHL to
traffic between nucleus and cytoplasm is decreased, even as the
mutation of the ubiquitylated site stabilizes VHL. Recently, Jung
et al reported that the cellular protein E2-EPF UCP degrades
VHL and stabilizes HIF [35]. Our present study further provides
evidence that deficiency of posttranslational modifications
at these lysines can disrupt VHL ability to target HIF1a.
Meanwhile, we also observed that PIASy expression and SUMO
modification can block VHL ubiquitylation, increase its protein
stability and nuclear localization. However, it remains to be
Figure 4. Ubiquitin/SUMO1 modification of VHL presents opposite effect on the VHL protein stability and subcellular localization.
(A) The effect of SUMO1 and ubiquitin modification on the VHL subcellular localization. 786-O cells transfected with VHL-SUMO1
DC4 or VHL-Ub
DGG
were cultured on coverslips, fixed with 3% paraformaldehyde, and then subjected to immunofluorescent assay followed by mouse anti-FLAG
antibody (green) and nuclear staining (blue) with DAPI as indicated. The percentage of cell staining pattern is calculated by total twenty positive
staining cells of each sample. (B) The effect of SUMO1 and ubiquitin modification on VHL protein stability. 786-O cells were cotransfected with
plasmids expressing VHL-SUMO1
DC4 or VHL-Ub
DGG alone. 48 h post-transfection, cell lysates treated with cycloheximide (CHX, 100 mg/ml) for 0, 1, 2
and 4 hours was subjected to immunoblot as indicated. b-Actin immunoblotting was used as the loading control. The relative quantitation of VHL is
shown in bottom panel. (C) Ubiquitin but not SUMO1 modification of VHL induces the ubiquitylation on lysine 196. 786-O cells were individually
cotransfected with expression vector encoding the indicated protein in the top panel. Forty-eight hour posttransfection, the cells were treated with
20 mM MG132 for 2 hrs before harvest. Cell extracts were subjected to immunoprecipitated (IP) and immunoblotting (IB) as indicated in the figure.
Blank arrows indicate the native VHL-SUMO1
DC4 or VHL-Ub
DGG; ubVHL, ubiquitylated VHL. The position of ubiquitylated VHL is highlighted by
asterisks. WCL, whole cell lysate; HC, heavy chain. (D) Immunoblotting analysis of nuclear and cytoplasm fraction of VHL with SUMO1/ubiquitin
modification. 786-O cells transfected with VHL-SUMO1
DC4 or VHL-Ub
DGG were subjected to nuclear (Nucl) and cytoplasm (Cyto) proteins extract
followed by immunoblotting against FLAG antibody. Nuclear protein Sp1 and cytoplasm protein b-actin were blotted as fraction positive control. ns,
non-specific band.
doi:10.1371/journal.pone.0012636.g004
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competition between these two modification states. Further
experiments will be required to explore these questions in more
detail.
Protein ubiquitin and ubiquitin-like posttranslational modifica-
tion has emerged as an important strategy for reversible
modification of many proteins that play regulatory roles in diverse
cellular processes, including protein relocalization, stability,
transcriptional control and stress response [29–31]. Many reports
have suggested that posttranslational modifications are an
important cellular strategy that enables the cell to react to
intracellular or environmental changes caused by exposure to
stress factors such as hypoxia [37,41]. Our previous studies have
shown that PIASy expression in response to hypoxic stress
negatively regulates VHL function as a tumor suppressor [32].
Here we further show that a single lysine mutation also impairs the
ability of VHL in terms of its inhibition of HIFa activity although
the level is reduced when compared with the SUMOylated
isoform. Therefore, there are many critical steps required for VHL
to fully function as a tumor suppressor protein, and the trafficking
between the nucleus and cytoplasm could be one of these critical
steps. Any block to this step will affect its antitumor activity. This
notion has been supported by three points of evidence: 1) Failure
of VHL to continuously shuttle between the nuclear and
cytoplasmic compartments leads to the stabilization of HIF1a
[27]; 2) Oxygen-dependent degradation of nuclear HIF1a is
dependent upon the dynamic nuclear-cytoplasmic trafficking of
VHL [26]; and 3) Acidosis blocks VHL nuclear-cytoplasmic
shuttling [42]. However, the impact of posttranslational modifi-
cation on VHL nuclear and cytoplasmic localization still remains
unclear. Our observation that SUMOylated VHL localizes to the
nucleus, while ubiquitylated VHL is cytoplasmic, suggests that
posttranslational modification may affect VHL subcellular local-
ization and its inhibitory function on HIFa.
Figure 5. The lysine 171/196 mutation abolishes the inhibitory function of VHL as a tumor suppressor.( A) The lysine 171/196 mutation
of VHL attenuates its inhibition on transcriptional activity of HIF-responsive reporter. 786-O cells were transiently transfected with wild type VHL or its
mutants in the presence of HRE-luciferase reporter. Empty vector was used as control. Data are presented as means6SD of three independent
experiments. The levels of exogenous VHL and endogenous HIF2a were individually detected by immunoblotting against FLAG and HIF2a. RD,
relative density. (B) The lysine 171/196 mutation of VHL loss its inhibitory effect on endothelial tube formation in vitro. The conditioned medium from
786-O cells expressing vector, wt VHL, or K171,196R, was tested for tube formation assay in vitro. Photographs were taken at 24 hr post-incubation. The
quantitation presents the average of the pattern/value association criterion from 5 random view fields per well. (C) A proposed model for the
dynamic regulation of VHL protein stability and nucleocytoplasmic distribution in tumor suppression. In some circumstance, interaction of VHL with
PIASy results in VHL nuclear localization, SUMOylation (Su) and stability for blocking ubiquitylation (Ub) of VHL. Meanwhile, PIASy dissociation with
VHL or attenuation of VHL SUMOylation facilitates VHL nuclear export, ubiquitylation and instability. This dynamic process of VHL with reversible
modification acts in a concert to inhibit HIFa. The ability of VHL with different isoforms on inhibition of HIFa transcriptional activity is indicated at the
bottom.
doi:10.1371/journal.pone.0012636.g005
Ub/SUMO Modified VHL
PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e12636Our data now demonstrate that SUMOylation and not
ubiquitylation at the C terminus of VHL contributes to the
nuclear import of VHL, and supports a model in which
SUMOylation of the C terminus of VHL, in a region close to
both the nuclear export and oligomerization sequences, blocks the
nuclear export signal and allows interaction of VHL with the
nuclear import machinery. Thus, the ability of VHL to shuttle
between the nucleus and the cytoplasm may contribute to its
antitumor property under specific physiologic conditions.
Materials and Methods
Cell culture and transfection
Human renal carcinoma VHL-null cell lines 786-O and
embryonic kidney (HEK) 293 cells were described as previously
[36], and maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 5% fetal bovine serum (FBS,
Hyclone), 4 mM L-glutamine, penicillin, and streptomycin [36].
Cells were incubated at 37uC in a humidified environmental
incubator supplemented with 5% CO2. Ten million cells with
400 ml medium were transfected by electroporation with a Bio-
Rad Gene Pulser in 0.4 cm-gap cuvettes at 210 Volts and 975
microfarads.
Plasmids, antibodies and reagents
Plasmid FLAG-VHL was provided individually by Joan W
Conaway (Stowers Institute for Medical Research, USA). Plasmids
encoding human PIASy with FLAG tag were gifts from Stefan
Mu ¨ller (Max Planck Institute of Biochemistry, Germany).
PIASyDC-FLAG (1-233) and PIASy-myc (1-492) were generated
by ligating BamHI/EcoRV PCR fragments into pcDNA-FLAG
and pA3M vector, respectively. Full length PIASy-RFP was
prepared by ligating KpnI/BamHI PCR fragments into pDs-Red-
N1 vector. VHL-Ub
DGG and VHL-SUMO1
DC4 were generated
by in-frame ligation of BamHI/XbaI PCR fragments to the
downstream of FLAG-VHL(K171R). FLAG-VHL (K171R),
(K196R), (K171,196R), (K159R), and (3KR), as well as VHL-
Ub
DGG (K196R) and VHL-SUMO1
DC4 (K196R) were individu-
ally generated by PCR site-directed mutagenesis. All constructs
were confirmed by direct DNA sequencing. Plasmids of pGL2-
HRE (HIFa-target reporter), and HA-Ub were previously
described [36,43]. The VHL antibodies were from Cell signaling
technology Inc. HIF2a antibodies were from Novus Biogicals Inc.
PIASy (I-19) and Sp1 (1C6) was purchased from Santa Cruz
Biotech. Inc. Other antibodies used were anti-myc (9E10), anti-
FLAG (M2), anti-HA (12CA5), and b-actin (Cell signaling
technology). Proteasome inhibitor MG132 was purchased from
Biomol International, and Cyclohexamide (C4859, Sigma Inc., St.
Louis, MO).
Immunofluorescence assay
Cells on coverslips were washed three times with PBS and then
fixed in 3% paraformaldehyde for 20 min at room temperature.
After fixation, cells were washed three times in PBS and
permeabilized in PBS containing 0.2% fish skin gelatin (G-7765,
Sigma), 0.2% Triton X-100 for 5 min, and then incubated for 1 h
at room temperature with primary antibodies in blocking solution.
Cells were washed three times with PBS and incubated for 30 min
at room temperature with fluorescently labeled Alexa fluors-488 or
594 against mouse or rabbit (Molecular Probes Inc., Eugene, OR)
in blocking solution. Coverslips were washed three times with PBS
and slides were mounted with Prolong antifade mounting medium
with 0.5 mM DAPI (49,6 9-diamidino-2-phenylindole). Fluores-
cence confocal microscopy was performed with an Olympus
microscope using FluoView
TM FV300 software (Olympus, Mel-
ville, NY).
Immunoblotting
Cells were harvested and washed once with ice-cold phosphate-
buffered saline (PBS) and lysed in 1 ml cold radioimmunoprecip-
itation assay (RIPA) buffer (50 mM Tris [pH 7.6], 150 mM NaCl,
2 mM EDTA, 1% Nonidet P-40, 1 mM PMSF, 1 mg/ml
aprotonin, 1 mg/ml leupeptin, 1 mg/ml pepstatin A) on ice and
homogenized. The cell lysates were resuspended in 50 mlo f1 6
SDS Laemmli buffer and heated 95uC for 5 minutes. The sample
was subjected to SDS-PAGE and transferred to a membrane that
was probed with specific antibody.
Determination of VHL stability
786-O cells were cotransfected FLAG-VHL with or without
FLAG-PIASy as described above. After 24 h transfection, cells
were incubated with 100 mM cyclohexamide for 0 to 4 hour and
then harvested. Equal amounts of total proteins from each
treatment were taken to perform western blot analysis.
Fractionation of nuclear or cytoplasm proteins
Twenty million transfected cells were harvested and washed
twice with ice-cold PBS followed by resuspending the cell pellet in
a hypotonic buffer A (10 mM HEPES-K
+ pH 7.5, 10 mM KCl,
1.5 mM MgCl2, 0.5 DTT) in the presence of protease inhibitor
cocktail (PIC: 1 mM PMSF, 10 mg/ml aprotinin, 10 mg/ml
leupeptin, 10 mg/ml pepstatin A). Cells were pelleted by spinning
at 1000 rpm65 min. The cells were lysated in ice-cold 0.5% NP-
40 containing buffer A with PIC on ice for 10 min. The nuclei
were pelleted by 3,000 rpm 62 min at 4uC. The supernatant
(cytoplasm protein) harvested and frozen at 280uC for use. The
nuclear pellets were washed twice with buffer A (without NP-40),
followed by resuspending in buffer C (20 mM HEPES-K
+ pH 7.9,
420 mM NaCl, 0.2 mM EDTA, 1.5 mM MgCl2, 0.5 DTT, 25%
Glycerol) with PIC. Nuclei were incubated on ice for 30 min, and
vortex periodically. Supernatant containing nuclear protein were
collected by spinning at 14,500 rpm for 5 min at 4uC and then
snap frozen for further use. Antibodies against nuclear protein Sp1
and cytoplasm protein b-Actin were used as markers.
RNA interference
The PIASy shRNA (59-GTACTTAAACGGACTGGGA-39)
sequence was inserted into lentivirus pGIPz vector according to
the manufacturer’s instructions (Clonetech). HEK293 cells were
individually transduction by lentivirus packaged from Core T
which cotransfected with Rev, VSVG and gp expressing plasmids,
and selection by 1 mg/ml Puromycin. pGIPz vector with luciferase
(shLuc) target (59-TGCGTTGCTAGTACCAAC-39) sequence
was used as control, and the RNA interfering efficiency was
assessed by western blot analysis.
Luciferase reporter assay
The luciferase reporter assays were performed as described
previously [36]. After transfection for 48 h, cells were lysed in
200 ml of reporter lysis buffer (Promega, Inc., Madison, WI).
Luciferase activities and b-galactosidase were individually measured
using luciferase assay reagent (Promega, Inc., Madison, WI) and the
OpticompI Luminometer (MGM Instruments, Inc. Hamden, CT)
according to the suppliers’ instructions. Luciferase activities were
normalized with b-galactosidase activities. Relative luciferase
activity (RLU) was expressed as fold activation relative to the
reporter construct alone. Assays were performed in triplicate.
Ub/SUMO Modified VHL
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Human umbilical vascular endothelial cells (HUVEC) were
purchased (Cambrex) and maintained in EBM-2 medium
supplemented with EGM-2. Tube formation assay on extracellular
BD matrigel was performed according to the manufacturer’s
protocol with minor modifications. Briefly, 2610
4 HUVEC
resuspended with 500 ml of EBM-2 medium were seeded on
Matrixgel solidified in 48-well tissue culture plate. Conditioned
medium (1 ml) from the supernatant of each 786-O stable cells
was added, respectively. Cells were incubated in a CO2 incubator
for 24 hrs at 37uC and then examined for tube formation with a
light microscope.
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